A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract …
JE Gray, E Haura, A Chiappori, T Tanvetyanon… - … Cancer Research, 2014 - AACR
… studies of erlotinib (18) and panobinostat (13). The pharmacokinetic parameters for erlotinib
and panobinostat (14) seen in this study are … patients was comparable with prior studies that …
and panobinostat (14) seen in this study are … patients was comparable with prior studies that …
The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells
G Greve, I Schiffmann, D Pfeifer, M Pantic, J Schüler… - BMC cancer, 2015 - Springer
… -HDACi PS with erlotinib. In this study, we could show that the combination of erlotinib with
PS … , was enhanced by erlotinib, an effect of the TKI that has not been described previously. …
PS … , was enhanced by erlotinib, an effect of the TKI that has not been described previously. …
A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma
… romidepsin, belinostat and panobinostat, proved their efficacy … I study reported that an HDACi
was well tolerated by patients with … using cell lines, recent studies have proposed the use of …
was well tolerated by patients with … using cell lines, recent studies have proposed the use of …
A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC
L Samaraweera, A Adomako, A Rodriguez-Gabin… - Scientific reports, 2017 - nature.com
… A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor,
combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer …
combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer …
Profile of panobinostat and its potential for treatment in solid tumors: an update
M Anne, D Sammartino, MF Barginear… - OncoTargets and …, 2013 - Taylor & Francis
… Comparable to the other HDACs, panobinostat leads to … Preclinical data suggests that
panobinostat has inhibitory activity … Here we review the current status of panobinostat and …
panobinostat has inhibitory activity … Here we review the current status of panobinostat and …
[HTML][HTML] A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer
F de Marinis, A Atmaca, M Tiseo, L Giuffreda… - Journal of Thoracic …, 2013 - Elsevier
… patients in a phase I trial in combination with erlotinib. Disease stabilization could be
considered a clinically relevant result in patients affected by SCLC in second-line setting. In this …
considered a clinically relevant result in patients affected by SCLC in second-line setting. In this …
Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation
AC Harttrampf, MEM da Costa, A Renoult… - BMC cancer, 2021 - Springer
… Enhanced combination effects were observed with erlotinib or EPZ011989–8 (Fig. 5A). … of
EGFR by panobinostat we explored further the combination of panobinostat to erlotinib at de-…
EGFR by panobinostat we explored further the combination of panobinostat to erlotinib at de-…
The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models
MJ LaBonte, PM Wilson, W Fazzone, J Russell… - Cancer research, 2011 - AACR
… Importantly, a recent study showed that panobinostat induced downregulation of EGFR in …
EGFR TKI erlotinib resulted in synergistic antiproliferative effects (19). An additional study also …
EGFR TKI erlotinib resulted in synergistic antiproliferative effects (19). An additional study also …
Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer
AA Tarhini, H Zahoor, B Mclaughlin… - … research, 2013 - ar.iiarjournals.org
… In conclusion, this phase I study demonstrated that addition of panobinostat to carboplatin …
dose level of panobinostat tested in this trial. HDAC inhibitors, such as panobinostat, remain a …
dose level of panobinostat tested in this trial. HDAC inhibitors, such as panobinostat, remain a …
Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling
… of first-line gefitinib and erlotinib over conventional cytotoxic chemotherapy, both in terms of
response rates and progression-free survival in patients with EGFR-mutant adenocarcinoma …
response rates and progression-free survival in patients with EGFR-mutant adenocarcinoma …
相关搜索
- japanese patients study of panobinostat
- gemcitabine and erlotinib in patients
- aerodigestive tract tumors study of panobinostat
- oral panobinostat in patients multicenter study
- dose escalation study of oral panobinostat
- panobinostat in pediatric patients
- trial of carboplatin panobinostat in patients
- histone deacetylase inhibitor panobinostat pretreated patients
- oral panobinostat lbh589 in japanese patients
- patients with lymphoma intravenous panobinostat
- oral panobinostat chemoradiotherapy in patients
- gemcitabine in patients phase 3 study
- pharmacokinetic and pharmacodynamic study of panobinostat
- hdac inhibitor study of panobinostat
- pancreatic adenocarcinoma erlotinib in patients
- oral panobinostat in patients open label